Frontier IP said its portfolio company Amprologix had won a contract worth £1.2m funded by the UK Department for Health and Social Care to accelerate development and scale up its lead antibiotic candidate to tackle antimicrobial resistant MRSA and related superbugs.
The contract would be used to make the company's epidermicin NI01 antibiotic ready for phase 1 human clinical trials during early 2021.
Epidermicin NI01, the lead candidate in a new family of epidermicin-based antibiotics, was being developed by Amprologix, a spin out from the University of Plymouth.
The company had already secured industry involvement. Ingenza, an industrial biotechnology and synthetic biology, also a shareholder, and Frontier IP held a 10% stake in return for providing a range of commercialisation services.
Amprologix's first product was expected to be a nasal cream containing NI01 to prevent MRSA infections.